Prevalence of Deleterious Variants in MC3R in Patients With Constitutional Delay of Growth and Puberty.
MC3R
ALSPAC
UK Biobank
constitutional delay
delayed puberty
Journal
The Journal of clinical endocrinology and metabolism
ISSN: 1945-7197
Titre abrégé: J Clin Endocrinol Metab
Pays: United States
ID NLM: 0375362
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
14
02
2023
medline:
20
11
2023
pubmed:
20
6
2023
entrez:
20
6
2023
Statut:
ppublish
Résumé
The melanocortin 3 receptor (MC3R) has recently emerged as a critical regulator of pubertal timing, linear growth, and the acquisition of lean mass in humans and mice. In population-based studies, heterozygous carriers of deleterious variants in MC3R report a later onset of puberty than noncarriers. However, the frequency of such variants in patients who present with clinical disorders of pubertal development is currently unknown. This work aimed to determine whether deleterious MC3R variants are more frequently found in patients clinically presenting with constitutional delay of growth and puberty (CDGP) or normosmic idiopathic hypogonadotropic hypogonadism (nIHH). We examined the sequence of MC3R in 362 adolescents with a clinical diagnosis of CDGP and 657 patients with nIHH, experimentally characterized the signaling properties of all nonsynonymous variants found and compared their frequency to that in 5774 controls from a population-based cohort. Additionally, we established the relative frequency of predicted deleterious variants in individuals with self-reported delayed vs normally timed menarche/voice-breaking in the UK Biobank cohort. MC3R loss-of-function variants were infrequent but overrepresented in patients with CDGP (8/362 [2.2%]; OR = 4.17; P = .001). There was no strong evidence of overrepresentation in patients with nIHH (4/657 [0.6%]; OR = 1.15; P = .779). In 246 328 women from the UK Biobank, predicted deleterious variants were more frequently found in those self-reporting delayed (aged ≥16 years) vs normal age at menarche (OR = 1.66; P = 3.90E-07). We have found evidence that functionally damaging variants in MC3R are overrepresented in individuals with CDGP but are not a common cause of this phenotype.
Identifiants
pubmed: 37339320
pii: 7204094
doi: 10.1210/clinem/dgad373
pmc: PMC10655545
doi:
Substances chimiques
Receptor, Melanocortin, Type 3
0
MC3R protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1580-e1587Subventions
Organisme : NICHD NIH HHS
ID : P50 HD104224
Pays : United States
Organisme : NICHD NIH HHS
ID : R01 HD090071
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_19009
Pays : United Kingdom
Organisme : NICHD NIH HHS
ID : R37 HD043341
Pays : United States
Organisme : Medical Research Council
ID : MC_PC_15018
Pays : United Kingdom
Organisme : Medical Research Council
ID : MC_UU_00014/5
Pays : United Kingdom
Organisme : Medical Research Council
ID : G9815508
Pays : United Kingdom
Commentaires et corrections
Type : CommentIn
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.
Références
J Clin Endocrinol Metab. 2002 Dec;87(12):5581-6
pubmed: 12466356
Mol Metab. 2017 Mar 01;6(5):383-392
pubmed: 28462073
J Clin Endocrinol Metab. 2021 Aug 18;106(9):e3693-e3703
pubmed: 33890108
Mol Endocrinol. 2014 Sep;28(9):1547-57
pubmed: 25051171
Genome Biol. 2016 Jun 06;17(1):122
pubmed: 27268795
J Clin Endocrinol Metab. 2002 Apr;87(4):1613-20
pubmed: 11932291
Nature. 2021 Nov;599(7886):628-634
pubmed: 34662886
Int J Epidemiol. 2013 Feb;42(1):111-27
pubmed: 22507743
Mol Metab. 2021 Jun;48:101206
pubmed: 33684608
Arq Bras Endocrinol Metabol. 2012 Dec;56(9):646-52
pubmed: 23329188
Nat Genet. 2017 Jun;49(6):834-841
pubmed: 28436984
EMBO Mol Med. 2016 Jun 01;8(6):626-42
pubmed: 27137492
Nat Methods. 2010 Apr;7(4):248-9
pubmed: 20354512
Wellcome Open Res. 2019 Mar 14;4:51
pubmed: 31020050
J Clin Endocrinol Metab. 2015 Apr;100(4):E646-54
pubmed: 25636053
Am J Hum Genet. 2018 Oct 4;103(4):522-534
pubmed: 30269813
Cell Genom. 2022 Dec 14;2(12):None
pubmed: 36530175
J Clin Endocrinol Metab. 2008 Mar;93(3):723-8
pubmed: 18160460
Sci Transl Med. 2021 Apr 21;13(590):
pubmed: 33883274
J Clin Endocrinol Metab. 2021 Nov 19;106(12):e5264-e5266
pubmed: 34223894
Nucleic Acids Res. 2003 Jul 1;31(13):3812-4
pubmed: 12824425
Biochem Biophys Res Commun. 2014 Nov 7;454(1):234-8
pubmed: 25450386
Nature. 2021 Nov;599(7885):436-441
pubmed: 34732894
Sci Rep. 2015 Jun 18;5:11208
pubmed: 26084728
Am J Hum Genet. 2013 May 2;92(5):725-43
pubmed: 23643382
Hum Mol Genet. 2020 Aug 11;29(14):2435-2450
pubmed: 32620954
Eur J Endocrinol. 2018 Apr;178(4):377-388
pubmed: 29419413
J Clin Endocrinol Metab. 2023 Nov 17;108(12):e1580-e1587
pubmed: 37339320
Nat Commun. 2020 Mar 24;11(1):1536
pubmed: 32210231
Int J Epidemiol. 2013 Feb;42(1):97-110
pubmed: 22507742
N Engl J Med. 2012 Feb 2;366(5):443-53
pubmed: 22296078
J Clin Endocrinol Metab. 2018 Sep 1;103(9):3420-3429
pubmed: 29931354
Endocr Rev. 2019 Oct 1;40(5):1285-1317
pubmed: 31220230
Nat Neurosci. 2017 Mar;20(3):484-496
pubmed: 28166221
Eur J Endocrinol. 2008 Apr;158(4):473-7
pubmed: 18362293
Nucleic Acids Res. 2019 Jan 8;47(D1):D886-D894
pubmed: 30371827